Little Green PharmaASX:LGP EBITDA Margin % is 6.37% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Little Green Pharma ranks worse than 64.4% on this metric.
Little Green Pharma (ASX:LGP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Little Green Pharma EBITDA Margin % Related Terms
Little Green Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Little Green Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Little Green Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Little Green Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Little Green Pharma (ASX:LGP) has a EBITDA Margin % of 6.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Little Green Pharma and its competitors. According to the industry distribution chart, Little Green Pharma ranks #615 out of 955 companies in the Drug Manufacturers industry, placing it in the top 64.4%.
Is Little Green Pharma's EBITDA Margin % too high?
Little Green Pharma's current EBITDA Margin % is 6.37%. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Little Green Pharma's value of 6.37% is 48.8% below this industry median. Based on the distribution chart, Little Green Pharma ranks #615 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Little Green Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Little Green Pharma ranks #615 out of 955 companies for EBITDA Margin %. This places Little Green Pharma in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Little Green Pharma's value of 6.37% is 48.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Little Green Pharma's current EBITDA Margin % of 6.37% is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Little Green Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Little Green Pharma's current EBITDA Margin % is 6.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.06 — trading 62.4% below its estimated fair value. The current EBITDA Margin % is 6.37% and 48.8% below the Drug Manufacturers industry median of 12.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current EBITDA Margin % is 6.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LGP has been successfully added to your 